SCHEMBL4671935

SCHEMBL4671935

O=C(Cc1occc1Sc1cccc(C(F)(F)F)c1)C(=O)c1nc[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
BRAF P15056 1/20 0.35
KDM4E B2RXH2 2/20 0.34
NOTUM Q6P988 1/20 0.34
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GPR52 Q9Y2T5 2/20 0.33
GRM5 P41594 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
GAA P10253 1/20 0.32
ATM Q13315 1/20 0.32
XDH P47989 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672116 0.88 HAO1 (0.32) SLC6A2SLC6A4SLC6A3BRAF
SCHEMBL4670990 0.86 SIRT2 (0.35) KDRSLC6A2SLC6A4SLC6A3SIRT2
SCHEMBL4675813 0.85 SLC6A9 (0.35) SLC6A2SLC6A4SLC6A3KDM4ENOTUM
SCHEMBL4676458 0.84 MTNR1A (0.36) SIRT2NOTUMMEN1KMT2A
SCHEMBL4675085 0.83 SLC6A2 (0.37) KDRSLC6A2SLC6A4SLC6A3SIRT2
SCHEMBL4674219 0.82 KDM4E (0.32) KDM4ENOTUM
SCHEMBL4672045 0.82 SIRT2 (0.37) SIRT2KDM4ENOTUMMEN1USP2
SCHEMBL4674661 0.81 SIRT2 (0.35) KDRSLC6A2SLC6A4SIRT2KDM4E
SCHEMBL4671080 0.81 SIRT2 (0.36) SIRT2KDM4ENOTUMMEN1USP2
SCHEMBL4671513 0.80 KDM4E (0.41) KDRBRAFKDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KDR 2342/4885SLC6A2 513/4885SLC6A4 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.